Effect-site Concentration of Remifentanil for Smooth Induction With Desflurane
Information source: Ajou University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anesthesia
Intervention: Remifentanil (Drug); Desflurane (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Ajou University School of Medicine Official(s) and/or principal investigator(s):
Yoonjeong Chae, MD, Study Chair, Affiliation: Ajou University School of Medicine
Summary
Desflurane is a halogenated ether with low solubility, giving rapid induction and emergence
from anesthesia This character is suitable for Volatile Induction and Maintenance Anesthesia
(VIMA). But desflurane can cause airway irritation when it used as a sole induction agent
to adult or children, so there were many studies about reducing the airway reflex combined
with desflurane.
Remifentanil is a short acting opioid and is quickly hydrolyzed by nonspecific esterase in
the plasma and multiorgan. Several studies suggest the optimal dose of remifentanil for
reducing airway reflex or cardiovascular response for intubation combined with desflurane.
But these studies were under 1 Minimal Alveolar Concentration (MAC) of desflurane and this
point could be a limitation because desflurane concentration over 1 MAC increase airway
irritation significantly. This study this study was designed to determine a median effective
effect-site concentration (EC50) of remifentanil to prevent airway irritation during
desflurane anesthesia over 1 MAC.
Clinical Details
Official title: Effect-site Concentration of Remifentanil for Smooth Induction With Desflurane
Study design: Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)
Primary outcome: Fail or success for induction with desflurane
Eligibility
Minimum age: 19 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients for surgery requiring general anesthesia
- American Society of Anesthesiologists(ASA) classification I, II
Exclusion Criteria:
- history of gastroesophageal reflux, High grade obesity, Predicted difficult airway,
Asthma, Chronic obstructive pulmonary disease(COPD), Upper respiratory infection
(URI) within 3 weeks
Locations and Contacts
Additional Information
Starting date: December 2014
Last updated: August 17, 2015
|
